Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks
by Sweta Killa
The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.
Implied Volatility Surging for Cytokinetics (CYTK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 10.71% and -22.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -5.66% and 4.88%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Amgen Starts Phase III Enrollment for Heart Failure Drug
by Zacks Equity Research
Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 12.73% and 171.40%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Cytokinetics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cytokinetics has been struggling lately, but the selling pressure may be coming to an end soon.
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?
by Zacks Equity Research
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
by Arpita Dutt
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.
Implied Volatility Surging for Cytokinetics (CYTK) Stock Options
by Zacks Equity Research
Cytokinetics (CYTK) needs Investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock
by Zacks Equity Research
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
New Strong Sell Stocks for May 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: